Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
- 159 Downloads
Tolvaptan [Jynarque® (USA); Jinarc® (EU, Canada); Samsca® (Japan)] is a highly selective vasopressin V2 receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). In the phase III TEMPO 3:4 trial, 3 years’ treatment with tolvaptan slowed the increase in total kidney volume (TKV) and the decline in renal function relative to placebo. The composite secondary endpoint of time to investigator-assessed clinical progression also favoured tolvaptan over placebo. Although tolvaptan did not demonstrate a sustained disease-modifying effect on TKV over the longer term in the TEMPO 4:4 extension trial, the effect of tolvaptan in slowing renal function decline was maintained for a further 2 years. The phase III REPRISE trial confirmed the efficacy of tolvaptan in patients with later-stage ADPKD. Most of the adverse events commonly observed with tolvaptan (e.g. polyuria, nocturia, polydipsia, thirst) are consistent with its pharmacological activity. In the TEMPO trials, tolvaptan was also associated with idiosyncratic hepatotoxicity which was reversible on discontinuation of the drug. Although the use of tolvaptan requires careful consideration and balancing of benefits and risks, it provides a valuable treatment option to slow the progression of ADPKD in patients at risk of or with evidence of rapidly progressing disease.
During the peer review process, the manufacturer of tolvaptan was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 7.European Medicines Agency. Jinarc (tolvaptan): EU summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 10 Jan 2019.
- 8.US FDA. JYNARQUE (tolvaptan) tablets for oral use: US prescribing information. 2018. http://www.fda.gov. Accessed 10 Jan 2019.
- 10.Torres VE, Chapman AB, Devuyst O, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol Dial Transplant. 2018;33(3):477–89.CrossRefGoogle Scholar
- 17.Chapman A, Devusyt O, Gansevoort R, et al. Potential impact of tolvaptan on blood pressure in the TEMPO 3:4 patient population [abstract no. FP047]. Nephrol Dial Transplant. 2018;33(Suppl 1):i63.Google Scholar
- 20.Yamada K, Muramoto H, Araki H, et al. Effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease patients with CKD stage G4: a retrospective multicenter study in Japan [abstract no. FP052]. Nephrol Dial Transplant. 2018;33(Suppl 1):i65.Google Scholar
- 21.Russmann S, Grimes E, Neidrig D, et al. Safety and efficacy of tolvaptan in the SUISSE ADPKD cohort [abstract no. 1386]. Drug Saf. 2018;41(11):1229.Google Scholar
- 22.Hattanda F, Nishio S, Takeda S, et al. Efficacy of tolvaptan on autosomal dominant polycystic kidney disease (ADPKD) patients in late stage CKD [abstract no. SP027]. Nephrol Dial Transplant. 2018;33(Suppl 1):i355.Google Scholar
- 23.Kai H, Tsunoda R, Kawamura T, et al. A prospective study of the efficacy and adverse effects of tolvaptan for autosomal dominant polycystic kidney disease (ADPKD) [abstract no. FP061]. Nephrol Dial Transplant. 2018;33(Suppl. 1):i68.Google Scholar
- 24.Cote G, Asselin-Thompstone L, Rene De Cotret P, et al. The impact of tolvaptan on glomerular filtration rate in patients with autostomal dominant polycystic kidney disease [abstract no. SA-PO476]. J Am Soc Nephrol. 2018;29(Suppl):859.Google Scholar
- 25.Honda K, Matsuura R, Ishimoto Y, et al. Association between initial dose of tolvaptan and reduction of total kidney volume in autostomal dominant polycystic kidney disease [abstract no. SA-PO477]. J Am Soc Nephrol. 2018;29(Suppl):859.Google Scholar
- 26.Kogure Y, Takayanagi K, Sato M, et al. Clinical features expecting high efficacy of tolvaptan in ADPKD patients [abstract no. SA-PO478]. J Am Soc Nephrol. 2018;29(Suppl):859.Google Scholar
- 27.Mueller R-U, Todorova P, Suarez V, et al. AD(H)PKD—a prospective cohort study on the use of tolvaptan in ADPKD [abstract no. SA-PO473]. J Am Soc Nephrol. 2018;29(Suppl):858.Google Scholar
- 30.McFarlane P, Bichet DG, Bergeron L, et al. Canadian real-life assessment of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD): C-MAJOR study and hepatic safety monitoring program [abstract no. SA-PO480]. J Am Soc Nephrol. 2018;29(Suppl):860.Google Scholar
- 32.Soroka S, Alam A, Bevilacqua M, et al. Updated Canadian expert consensus on assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease. Can J Kidney Health Dis. 2018. https://doi.org/10.1177/2054358118801589.
- 34.Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2016;31(3):337–48.CrossRefGoogle Scholar
- 35.National Institute for Health and Care Excellence (NICE). Tolvaptan for treating autosomal dominant polycystic kidney disease. 2015. http://www.nice.org.uk. Accessed 10 Jan 2019.
- 40.UKidney. Water vs tolvaptan in reducing ADPKD progression. http://ukidney.com. Accessed 10 Jan 2019.
- 44.European Medicines Agency. Jinarc assessment report. 2015. http://www.ema.europa.eu. Accessed 10 Jan 2019.
- 45.US National Institutes of Health. 2018. http://www.clinicaltrials.gov. Accessed 10 Jan 2019.
- 46.Blanchette CM, Matter S, Chawla A, et al. Burden of autosomal dominant polycystic kidney disease: systemic literature review. Am J Pharm Benefits. 2015;7(2):e27–36.Google Scholar
- 47.Bennett H, McEwan P, Robinson P, et al. Validation of the ADPKD outcomes model to a Spanish setting and an evaluation of the impact of treatment on the burden of ESRD [abstract no. PUK23 plus poster]. Value Health. 2017;20(5):A309–A10.Google Scholar
- 48.Shephard C, Delavelle C, Riemer J, et al. Impact of tolvaptan on costs associated with renal pain and chronic kidney disease among patients with autosomal dominant polycystic kidney disease [abstract no. 274]. Am J Kidney Dis. 2018;71(4):584.Google Scholar
- 51.Fujiki T, Ando F, Isobe K, et al. Tolvaptan activates Nrf2/HO-1 pathway through PERK phosphorylation [abstract no. SA-PO847]. J Am Soc Nephrol. 2018;29(Suppl):957.Google Scholar
- 58.Al Therwani S, Malmberg MES, Rosenbaek JB, et al. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. BMC Nephrol. 2017;18(1):268.CrossRefGoogle Scholar
- 60.Malmberg M, Sonderbaek R, Mose F, et al. Effect of tolvaptan on renal plasma flow and glomerular filtration in polycystic kidney disease [abstract no. SP110]. Nephrol Dial Transplant. 2018;33(Suppl 1):i381.Google Scholar